My NCBISign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 837

    1.

    Antigenic presentation of heterologous epitopes engineered into the outer surface-exposed helix 4 loop region of human papillomavirus L1 capsomeres.

    Murata Y, Lightfoote PM, Rose RC, Walsh EE.

    Virol J. 2009 Jun 18;6:81.PMID: 19538743 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Chimeric human papillomavirus type 16 (HPV-16) L1 particles presenting the common neutralizing epitope for the L2 minor capsid protein of HPV-6 and HPV-16.

    Varsani A, Williamson AL, de Villiers D, Becker I, Christensen ND, Rybicki EP.

    J Virol. 2003 Aug;77(15):8386-93.PMID: 12857908 [PubMed - indexed for MEDLINE]Related articlesFree article

    3.

    An HPV 16 L1-based chimeric human papilloma virus-like particles containing a string of epitopes produced in plants is able to elicit humoral and cytotoxic T-cell activity in mice.

    Paz De la Rosa G, Monroy-García A, Mora-García Mde L, Peña CG, Hernández-Montes J, Weiss-Steider B, Gómez-Lim MA.

    Virol J. 2009 Jan 6;6:2.PMID: 19126233 [PubMed - indexed for MEDLINE]Related articlesFree article

    4.

    A papillomavirus-like particle (VLP) vaccine displaying HPV16 L2 epitopes induces cross-neutralizing antibodies to HPV11.

    Slupetzky K, Gambhira R, Culp TD, Shafti-Keramat S, Schellenbacher C, Christensen ND, Roden RB, Kirnbauer R.

    Vaccine. 2007 Mar 1;25(11):2001-10. Epub 2006 Nov 29.PMID: 17239496 [PubMed - indexed for MEDLINE]Related articles

    5.

    Mutations on the FG surface loop of human papillomavirus type 16 major capsid protein affect recognition by both type-specific neutralizing antibodies and cross-reactive antibodies.

    Carpentier GS, Fleury MJ, Touzé A, Sadeyen JR, Tourne S, Sizaret PY, Coursaget P.

    J Med Virol. 2005 Dec;77(4):558-65.PMID: 16254978 [PubMed - indexed for MEDLINE]Related articles

    6.

    Human papillomavirus type 16 L1 capsomeres induce L1-specific cytotoxic T lymphocytes and tumor regression in C57BL/6 mice.

    Ohlschläger P, Osen W, Dell K, Faath S, Garcea RL, Jochmus I, Müller M, Pawlita M, Schäfer K, Sehr P, Staib C, Sutter G, Gissmann L.

    J Virol. 2003 Apr;77(8):4635-45.PMID: 12663770 [PubMed - indexed for MEDLINE]Related articlesFree article

    7.

    Concatenated multitype L2 fusion proteins as candidate prophylactic pan-human papillomavirus vaccines.

    Jagu S, Karanam B, Gambhira R, Chivukula SV, Chaganti RJ, Lowy DR, Schiller JT, Roden RB.

    J Natl Cancer Inst. 2009 Jun 3;101(11):782-92. Epub 2009 May 26.PMID: 19470949 [PubMed - indexed for MEDLINE]Related articlesFree article

    8.

    Co-vaccination with adeno-associated virus vectors encoding human papillomavirus 16 L1 proteins and adenovirus encoding murine GM-CSF can elicit strong and prolonged neutralizing antibody.

    Liu DW, Chang JL, Tsao YP, Huang CW, Kuo SW, Chen SL.

    Int J Cancer. 2005 Jan 1;113(1):93-100.PMID: 15386434 [PubMed - indexed for MEDLINE]Related articles

    9.

    Analysis of modified human papillomavirus type 16 L1 capsomeres: the ability to assemble into larger particles correlates with higher immunogenicity.

    Schädlich L, Senger T, Gerlach B, Mücke N, Klein C, Bravo IG, Müller M, Gissmann L.

    J Virol. 2009 Aug;83(15):7690-705. Epub 2009 May 20.PMID: 19457985 [PubMed - indexed for MEDLINE]Related articlesFree article

    10.

    Modification of human papillomavirus-like particle vaccine by insertion of the cross-reactive L2-epitopes.

    Kondo K, Ochi H, Matsumoto T, Yoshikawa H, Kanda T.

    J Med Virol. 2008 May;80(5):841-6.PMID: 18360909 [PubMed - indexed for MEDLINE]Related articles

    11.

    Identification of two cross-neutralizing linear epitopes within the L1 major capsid protein of human papillomaviruses.

    Combita AL, Touzé A, Bousarghin L, Christensen ND, Coursaget P.

    J Virol. 2002 Jul;76(13):6480-6.PMID: 12050360 [PubMed - indexed for MEDLINE]Related articlesFree article

    12.

    Crystal structures of four types of human papillomavirus L1 capsid proteins: understanding the specificity of neutralizing monoclonal antibodies.

    Bishop B, Dasgupta J, Klein M, Garcea RL, Christensen ND, Zhao R, Chen XS.

    J Biol Chem. 2007 Oct 26;282(43):31803-11. Epub 2007 Sep 4.PMID: 17804402 [PubMed - indexed for MEDLINE]Related articlesFree article

    13.

    A direct comparison of human papillomavirus type 16 L1 particles reveals a lower immunogenicity of capsomeres than viruslike particles with respect to the induced antibody response.

    Thönes N, Herreiner A, Schädlich L, Piuko K, Müller M.

    J Virol. 2008 Jun;82(11):5472-85. Epub 2008 Apr 2.PMID: 18385253 [PubMed - indexed for MEDLINE]Related articlesFree article

    14.

    Efficiency of HPV 16 L1/E7 DNA immunization: influence of cellular localization and capsid assembly.

    Kuck D, Leder C, Kern A, Müller M, Piuko K, Gissmann L, Kleinschmidt JA.

    Vaccine. 2006 Apr 5;24(15):2952-65. Epub 2005 Dec 29.PMID: 16414157 [PubMed - indexed for MEDLINE]Related articles

    15.

    Baculovirus expression of the respiratory syncytial virus fusion protein using Trichoplusia ni insect cells.

    Parrington M, Cockle S, Wyde P, Du RP, Snell E, Yan WY, Wang Q, Gisonni L, Sanhueza S, Ewasyshyn M, Klein M.

    Virus Genes. 1997;14(1):63-72.PMID: 9208456 [PubMed - indexed for MEDLINE]Related articles

    16.

    Oral immunization with different assembly forms of the HPV 16 major capsid protein L1 induces neutralizing antibodies and cytotoxic T-lymphocytes.

    Thönes N, Müller M.

    Virology. 2007 Dec 20;369(2):375-88. Epub 2007 Sep 5.PMID: 17822733 [PubMed - indexed for MEDLINE]Related articles

    17.

    Characterization of neutralizing epitopes within the major capsid protein of human papillomavirus type 33.

    Roth SD, Sapp M, Streeck RE, Selinka HC.

    Virol J. 2006 Oct 2;3:83.PMID: 17014700 [PubMed - indexed for MEDLINE]Related articlesFree article

    18.

    Deletion of a major neutralizing epitope of human papillomavirus type 16 virus-like particles.

    Ryding J, Dahlberg L, Wallen-Ohman M, Dillner J.

    J Gen Virol. 2007 Mar;88(Pt 3):792-802.PMID: 17325351 [PubMed - indexed for MEDLINE]Related articlesFree article

    19.

    Chimeric L1-L2 virus-like particles as potential broad-spectrum human papillomavirus vaccines.

    Schellenbacher C, Roden R, Kirnbauer R.

    J Virol. 2009 Oct;83(19):10085-95. Epub 2009 Jul 29.PMID: 19640991 [PubMed - indexed for MEDLINE]Related articles

    20.

    Enhancement of vaccine potency by fusing modified LTK63 into human papillomavirus type 16 chimeric virus-like particles.

    Xu Y, Zhang H, Xu X.

    FEMS Immunol Med Microbiol. 2008 Jan;52(1):99-109. Epub 2007 Nov 7.PMID: 17995958 [PubMed - indexed for MEDLINE]Related articles

    Display Settings:

    Format
    Items per page
    Sort by

    Send to:

    Choose Destination

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity

    You are here: NCBI > Literature > PubMed
    Write to the Help Desk